ArticleRadiology2022
Extensive Brain Pathologic Alterations Detected with 7.0-T MR Spectroscopic Imaging Associated with Disability in Multiple Sclerosis.
Article in Radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- The Emerging Role of N-Acetylaspartate in Cancer.International journal of molecular sciences · 2026Review
- MRS4Brain: a software for preclinical proton and deuterium-based MR spectroscopic imaging data.Magma (New York, N.Y.) · 2026Article
- Multiplexed magnetic resonance imaging.Nature · 2026Article
- Metabolic changes in normal-appearing white matter associate with MRI measures of disease burden in relapsing-remitting multiple sclerosis over three years.Scientific reports · 2026Article
- Biomarkers of Progression Independent of Relapse Activity-Can We Actually Measure It Yet?International journal of molecular sciences · 2025Review
- Automated Quantitative Susceptibility and Morphometry MR Study: Feasibility and Interrelation Between Clinical Score, Lesion Load, Deep Grey Matter and Normal-Appearing White Matter in Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2024Article
- Ultrahigh-field MRI: where it really makes a difference.Radiologie (Heidelberg, Germany) · 2024Review
- Decoding Gray Matter Involvement in Multiple Sclerosis via Imaging.Neuroimaging clinics of North America · 2024Review
- Association of Cortical Lesions With Regional Glutamate, GABA,Neurology · 2024Article
- Whole-brain deuterium metabolic imaging via concentric ring trajectory readout enables assessment of regional variations in neuronal glucose metabolism.Human brain mapping · 2024Article
- Proteomics analysis of periplaque and chronic inactive multiple sclerosis lesions.Frontiers in molecular neuroscience · 2024Article
- Differentiation of hemispheric white matter lesions in migraine and multiple sclerosis with similar radiological features using advanced MRI.Frontiers in neuroscience · 2024Article
- The use of 7T MRI in multiple sclerosis: review and consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.Brain communications · 2024Review
- Multiparametric magnetic resonance imaging for detection of pathological changes in the central nervous system of a mouse model of multiple sclerosis in vivo.NMR in biomedicine · 2023Article
- Quantitative myelin imaging with MRI and PET: an overview of techniques and their validation status.Brain : a journal of neurology · 2023Review
- Brain Pathology in Multiple Sclerosis with High-Field-Strength MR Spectroscopic Imaging.Radiology · 2022Article
- Framework to Segment and Evaluate Multiple Sclerosis Lesion in MRI Slices Using VGG-UNet.Computational intelligence and neuroscience · 2022Article
- Astrocytic function is associated with both amyloid-β and tau pathology in non-dementedBrain communications · 2022Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background MR spectroscopic imaging (MRSI) allows in vivo assessment of brain metabolism and is of special interest in multiple sclerosis (MS), where morphologic MRI cannot depict major parts of disease activity. Purpose To evaluate the ability of 7.0-T MRSI to depict and visualize pathologic alterations in the normal-appearing white matter (NAWM) and cortical gray matter (CGM) in participants with MS and to investigate their relation to disability. Materials and Methods Free-induction decay MRSI was performed at 7.0 T. Participants with MS and age- and sex-matched healthy controls were recruited prospectively between January 2016 and December 2017. Metabolic ratios were obtained in white matter lesions, NAWM, and CGM regions. Subgroup analysis for MS-related disability based on Expanded Disability Status Scale (EDSS) scores was performed using analysis of covariance. Partial correlations were applied to explore associations between metabolic ratios and disability. Results Sixty-five participants with MS (mean age ± standard deviation, 34 years ± 9; 34 women) and 20 age- and sex-matched healthy controls (mean age, 32 years ± 7; 11 women) were evaluated. Higher signal intensity of myo-inositol (mI) with and without reduced signal intensity of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.